Cerevel Therapeutics Holdings logo
Cerevel Therapeutics Holdings CERE

Quarterly report 2024-Q1
added 05-08-2024

report update icon

Cerevel Therapeutics Holdings Financial Ratios 2011-2026 | CERE

Annual Financial Ratios Cerevel Therapeutics Holdings

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-15.4 -11.4 -19.6 -8.0 - - - - - - - - -

EPS

-2.7 -2.3 -1.6 -2.0 -2.9 - - - - - - - -

EV (Enterprise Value)

6.84 B 4.36 B 4.34 B 833 M -83.7 M -95.4 M - - 6.91 M 4.82 M 4.17 M 6.69 M -

EBITDA per Share

-2.73 -2.4 -1.59 -2.02 - - - - - - - - -

EV/EBITDA

-19.7 - - - - - - - - - -

P/B

9.9 7.7 7.7 - - - - - - - - - -

P/CF

-19.5 -13.6 -24.8 -10.4 - - - - - - - - -

ROE %

-64.24 -67.44 -38.94 -39.57 - - - - - - - - -

ROA %

-34.81 -34.54 -32.71 - - - - - - - - - -

ROCE %

-66.38 -70.57 -38.03 -38.78 - - - - - - - - -

Current Ratio

2.2 2.0 6.3 - - - - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Cerevel Therapeutics Holdings

2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.73 - -0.61 -0.63 -0.67 - -0.66 -0.61 -0.46 - -0.43 -0.42 -0.4 - -0.62 -0.44 -0.87 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

-0.78 - - - -0.63 - -0.6 -0.63 -0.48 - -0.37 -0.4 -0.4 - -0.54 -0.57 -0.62 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-122.37 -87.86 -104.42 -85.68 -77.26 -49.64 -59.50 -52.81 -50.94 -42.97 -53.13 -53.41 -42.25 -30.94 -30.94 -20.79 -13.84 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-46.28 -34.06 -43.20 -40.61 -40.53 -31.22 -39.68 -27.96 -41.58 -34.57 -43.34 -43.64 -36.03 -26.72 -26.72 -17.95 -11.95 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-134.46 -91.47 -107.22 -82.20 -75.11 -50.20 -58.87 -51.78 -48.43 -40.73 -49.66 -49.93 -41.89 -27.88 -27.88 -18.95 -9.80 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

2.0 2.2 1.5 1.6 1.9 2.0 2.2 - 6.4 6.2 7.0 4.0 6.0 7.3 7.3 7.3 7.3 2.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Cerevel Therapeutics Holdings, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.25 1.81 % $ 908 M israelIsrael
BioNTech SE BioNTech SE
BNTX
$ 91.28 0.11 % $ 27.2 B germanyGermany
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
$ 330.34 3.6 % $ 43.3 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 0.44 -16.64 % $ 5.04 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
$ 24.98 1.17 % $ 3.05 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 10.14 -0.29 % $ 135 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.58 - $ 106 M usaUSA
Curis Curis
CRIS
$ 0.53 -3.07 % $ 6.98 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 37.7 1.26 % $ 3.55 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 49.15 -0.73 % $ 4.42 B schweizSchweiz
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
$ 2.96 -1.0 % $ 252 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 4.4 -3.51 % $ 607 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.86 0.67 % $ 5.79 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 0.18 -1.61 % $ 17.1 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
- 10.36 % $ 9.8 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.09 -0.97 % $ 437 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 4.15 -32.52 % $ 10.4 M usaUSA
Daré Bioscience Daré Bioscience
DARE
$ 1.81 4.02 % $ 20.2 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 20.36 -3.32 % $ 2.84 B franceFrance
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 8.22 2.37 % $ 225 M israelIsrael
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 19.38 -6.15 % $ 3.19 B usaUSA
Dyadic International Dyadic International
DYAI
$ 0.87 -2.8 % $ 31.5 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.37 1.0 % $ 2.08 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA